ST. LOUIS — Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced that LifeSpan Biosciences, a TSCP portfolio company, has become Absolute Biotech, a unified holding company joining together leading antibody-centric brands from around the world. Absolute Biotech specializes in antibody reagents and services, adding value to existing antibodies, reagents and kits through annotation, validation, sequencing, engineering and recombinant manufacturing. The combined company will leverage each brand’s unique antibody expertise to advance the creation and availability of highly defined life science reagents. TSCP acquired LifeSpan Biosciences in 2018.
“We are very excited to launch Absolute Biotech and unite multiple life science brands into one integrated company that offers more to its customers,” said CEO Dr. Heather Holemon. “Our combined company mission is to serve as antibody curators for customers worldwide, treating each antibody like a work of art to deliver unique and absolutely defined reagents that empower scientists. We are eager for what the future holds, as we continue to merge unique product portfolios and wide-ranging antibody expertise to provide better access to the reproducible reagents researchers need.”
Absolute Biotech offers customers worldwide the full breadth of antibody-related products, services and expertise for research, diagnostic and therapeutic applications. The company unites a strong recombinant antibody portfolio with expertise in antibody engineering and application-specific validation to make sequence-defined, reproducible reagents more widely available for immunohistochemistry and other key applications. Together, the brands offer more than one million off-the-shelf life science reagents, as well as custom antibody sequencing, antibody engineering and recombinant antibody expression services.
Brands within the Absolute Biotech family include:
- Absolute Antibody, experts in antibody engineering and recombinant antibody technology
- LSBio, leaders in IHC validation with a comprehensive catalog of antibodies, proteins and ELISAs
- Kerafast, which facilitates access to unique laboratory-made research tools
- Nordic-MUbio, which develops antibody and flow cytometry reagents according to ISO 9001 guidelines
- Everest Biotech, specialists in anti-peptide and antigen affinity purified goat polyclonal antibodies
- Exalpha, which offers cutting-edge antibodies, reagents, kits and custom IgY services
About Thompson Street Capital Partners
Thompson Street Capital Partners (TSCP) is a St. Louis-based private equity firm focused on investing in founder-led middle market businesses. We have acquired more than 150 companies in the Healthcare & Life Science Services, Software & Technology Services and Business Services & Engineered Products sectors and have managed more than $3.6 billion since being founded in 2000. TSCP partners with management teams to increase value by accelerating growth, both organically and via complementary acquisitions.